PMS-PIROXICAM CAPSULE

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

PIROXICAM

제공처:

PHARMASCIENCE INC

ATC 코드:

M01AC01

INN (국제 이름):

PIROXICAM

복용량:

20MG

약제 형태:

CAPSULE

구성:

PIROXICAM 20MG

관리 경로:

ORAL

패키지 단위:

100 - 500

처방전 유형:

Prescription

치료 영역:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

제품 요약:

Active ingredient group (AIG) number: 0114612001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2016-10-28

제품 특성 요약

PRODUCT MONOGRAPH
Pr
pms-PIROXICAM
Piroxicam, USP
10 mg and 20 mg Capsules
10 mg and 20 mg Suppositories
Nonsteroidal Anti-Inflammatory Drug (NSAID)
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue
February 17, 2010
Montreal, Quebec
H4P 2T4
CONTROL # 131400
_ _
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
.................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL
PHARMACOLOGY.............................................................23
STORAGE AND
STABILITY..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................24
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL
INFORMATION..........................................................................26
CLINICAL TRIALS
..........................................................................................................27
DETAILED PHARMACOLOGY
.....................................................................................27